favipiravir / Generic mfg. - LARVOL DELTA

Trends and Advances in Analytical Methodologies for Favipiravir Determination Across Diverse Matrices. (PubMed, Crit Rev Anal Chem) - "However, incomplete validation and robustness assessment remain limitations in several reported methods. Overall, this review provides a comparative perspective on favipiravir analytical strategies and highlights future needs for standardized, sensitive, sustainable, and intelligent analytical methods."

Journal • Review • Infectious Disease

Calu-3 cells as novel efficient cell culture system for Borna disease virus 1 (BoDV-1). (PubMed, Virus Res) - "Notably, favipiravir (T-705), a drug with a described cell-type dependent inhibitory activity against BoDV-1 in vitro, which has been used as an off-label therapy in some cases of human BoDV-1 infection, did not reduce BoDV-1 RNA shedding into the supernatant of permanently infected Calu-3 cells and had only a limited effect in a de-novo infection model. In conclusion, our results underline the broad viral tropism of BoDV-1 in vitro and first describe a high release efficiency for BoDV-1 RNA in Calu-3 cells."

Journal • Preclinical • Brain Cancer • CNS Disorders • Glioma • Infectious Disease • Oligodendroglioma • Oncology • Solid Tumor

Lethal C57BL/6 mouse model for Yezo virus infection and antiviral therapeutic evaluation. (PubMed, Emerg Microbes Infect) - "Antiviral evaluation demonstrated that both favipiravir and ribavirin significantly suppressed in vivo YEZV replication, improved survival, and reduced hepatic viral burden. Collectively, this model establishes a rigorously validated platform for mechanistic studies of YEZV pathogenesis and the preclinical evaluation of antiviral therapeutics."

Journal • Preclinical • Hematological Disorders • Hepatology • Infectious Disease • Inflammation • Leukopenia • Liver Failure • Thrombocytopenia

Treatment of CCHF with supportive care, favipiravir, and avatrombopag. (PubMed, Clin Infect Dis) - "This multimodal approach was associated with rapid platelet recovery, reduced transfusion requirements, and viral clearance. Combining targeted antivirals with thrombopoietin receptor agonists represents a promising strategy for managing severe CCHF coagulopathy."

Journal • Hematological Disorders

Influenza A deletion-containing viral genome production is altered by metabolites, metabolic signaling molecules, and cyanobacterial extracts. (PubMed, Appl Environ Microbiol) - "We recently showed that altering host cell metabolism away from pro-growth pathways using alpelisib increased the production of influenza A nonstandard viral genomes (specifically deletion-containing viral genomes, DelVGs)...Tricarboxylic acid (TCA) cycle inhibitors, 4-octyl itaconate and UK5099, along with the purine analog favipiravir, increased total viral genome production across subtypes...Our findings suggest that the social interactions observed between defective and full-length viral genomes depend not only on the viral actors but can also be altered by the stage provided by the host. Our findings have potential applications to increasing DelVG production for research or industrial uses; employing metabolites as biomarkers for flu infection severity; and using drugs to alter host metabolism to steer influenza infections to milder outcomes."

Journal • Infectious Disease • Influenza • Respiratory Diseases

Activated Sludge in the Bioremediation of Water Containing SARS-CoV-2 Antivirals. (PubMed, J Xenobiot) - "This study evaluates the removal percentages, kinetic mechanisms, and toxicity profiles of six SASs, daclatasvir (DCV), darunavir (DRV), favipiravir (FAV), lopinavir (LOP), remdesivir (REM), and ritonavir (RIT), using activated sludge. Perturbation analysis showed that all tested factors have a distinct influence on process performance. These established kinetic trends should support further investigations into advanced biological wastewater treatment methods and precise ecotoxicity profiling of emerging biotransformation products."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Study protocol for a phase II clinical trial evaluating the safety and efficacy of favipiravir injection combined with oseltamivir in influenza treatment. (PubMed, BMJ Open) - "Study findings will be disseminated through peer-reviewed publications and/or presentations at academic conferences. jRCT2031240586."

Clinical protocol • Journal • P2 data • Critical care • Infectious Disease • Influenza • Pneumonia • Respiratory Diseases

Antibody engineering for SFTS treatment: frontier progress and translational challenges. (PubMed, Front Microbiol) - "Severe Fever with Thrombocytopenia Syndrome (SFTS), a highly fatal tick-borne infectious disease caused by SFTS virus (SFTSV), currently lacks globally approved specific antiviral drugs or vaccines, although favipiravir was approved in Japan for SFTS treatment in June 2024 based on data from non-randomized, uncontrolled single-arm trials...It analyzes translational challenges-including immunogenicity, manufacturing processes, cost control, drug resistance, and clinical trial design-and proposes a strategic prioritization matrix and future research directions such as multispecific antibody development, artificial intelligence (AI)-assisted design, combination therapy strategies, and international multicenter collaboration. This review aims to provide a systematic reference for the clinical translation of SFTS antibody therapeutics."

Journal • Review • Hematological Disorders • Infectious Disease • Thrombocytopenia

Long-Term Survival of Borna Disease Virus 1 (BoDV-1)-Encephalitis: An Exceptional Case with Valuable Insights for Pathophysiology and Disease Management. (PubMed, Infect Dis Ther) - "This exceptional case with long-term survival in BoDV-1 encephalitis gives important insights: BoDV1-associated neuroinflammation leading to a slowly progressive decline can be visualized by TSPO-PET. Late BoDV-1 RNA detection and subacute re-exacerbation after prolonged survival provides evidence that BoDV-1 persists in human brain tissue."

Journal • CNS Disorders • Inflammation • Ocular Inflammation • Sleep Disorder

UMIT-2 - Adaptive Phase IIb Platform Trial to Determine the Efficacy and Safety of Therapeutics for CCHF (clinicaltrials.gov) - P2 | N=378 | Recruiting | Sponsor: Liverpool School of Tropical Medicine | Not yet recruiting ➔ Recruiting

Enrollment open • Hematological Disorders

Anti-CD20 associated enterovirus meningoencephalitis: A narrative review with two illustrative cases. (PubMed, Mult Scler J Exp Transl Clin) - "Of 42 cases, 34 were associated with rituximab and eight with ocrelizumab...IVIg or subcutaneous immunoglobulin (SCIg) was used in 36 cases, steroids in seven, fluoxetine in six, pocapavir in two, pleconaril in two, and ribavirin/favipiravir in one...CSF PCR aids diagnosis, though alternative specimens may be required. Early IVIg and investigational antivirals may be considered."

Journal • Review • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Glomerulonephritis • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Multiple Sclerosis • Nephrology • Oncology • Ophthalmology • Pain • Renal Disease

How Feasible is the Use of Saliva for Antiviral Therapeutic Drug Monitoring? A Systematic Review and Analysis. (PubMed, Clin Pharmacokinet) - "Studies documenting both saliva and plasma concentrations were scarce, and data was inconsistent. Findings from clinical studies sometimes contradicted predictions of penetration based on drug properties, suggesting that other factors, such as drug transporters, may significantly influence the salivary excretion of antivirals. Future robust, standardised investigations are required to confirm the clinical utility of saliva-based TDM. Feasibility is therefore currently inconclusive, but preliminary evidence is promising."

Journal • Review • Infectious Disease

The relationship between plasma favipiravir concentrations and clinical outcomes in COVID-19. (PubMed, ERJ Open Res) - "Most patients did not reach target favipiravir levels. Concentrations were influenced by sex, body mass index and liver function, confirming the need for pharmacokinetically guided dosing and therapeutic monitoring to optimise antiviral efficacy in future pandemic responses."

Clinical data • Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Baloxavir marboxil, favipiravir, or oseltamivir in patients with non-severe symptomatic seasonal influenza (AD ASTRA): a phase 2, open-label, adaptive, randomised controlled trial. (PubMed, Lancet Infect Dis) - P2 | "Oral baloxavir, favipiravir, and oseltamivir accelerated influenza viral clearance rates in adults with early non-severe seasonal influenza at low risk of progression to severe disease. Baloxavir had the greatest in-vivo antiviral efficacy, followed by favipiravir and oseltamivir. These antivirals shortened fever duration but showed no clear effects on time to complete symptom resolution. This pharmacometric approach can inform prioritisation of antiviral agents for further study and potential inclusion in pandemic stockpiles."

Journal • P2 data • CNS Disorders • Infectious Disease • Influenza • Respiratory Diseases

In silico study: ADMET-driven pharmacokinetic profiling of antiviral compounds for pre-clinical screening framework of intranasal drug development. (PubMed, J Pharmacol Toxicol Methods) - "This study employed computational ADMET Predictor tools to systematically evaluate the physicochemical and potential pharmacokinetic properties of ten reference compounds, including nine approved antiviral drugs and ivermectin, a repurposed antiparasitic agent with reported antiviral activity and prior intranasal investigation: Zanamivir, Ribavirin, Oseltamivir, Favipiravir, Remdesivir, Nitazoxanide, Acyclovir, Lopinavir, Molnupiravir, and Ivermectin...The analysis resulted in revised criteria including molecular weight (Mwt), pH, lipophilicity (Log P), water solubility (Sw and SpH), Volume of distribution (Vd), P-glycoproteins substrate (Pgp substrate), and skin sensitization (Sens_Skin) to demonstrate 80% concordance with approved drug properties. This framework provides the preliminary evidence-based screening criteria as a tool to identify promising drug candidates suitable for preclinical evaluation in intranasal formulation development."

Journal • PK/PD data • Preclinical • Developmental Disorders • Infectious Disease • Influenza • Novel Coronavirus Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Gut dysbiosis, anxiety and depression and the neurotoxic effects of formulated favipiravir and the restorative impact of vitamin D supplementation in adult zebrafish. (PubMed, J Food Sci Technol) - "Therefore, favipiravir exposure in sub-lethal doses causes neurotoxicity in the zebrafish model, and vitamin D showed a supplementary effect by restoring homeostasis. The online version contains supplementary material available at 10.1007/s13197-025-06255-6."

Journal • CNS Disorders • Depression • Infectious Disease • Mood Disorders • Novel Coronavirus Disease • Pain • Psychiatry • BDNF • CAT • TSHB

Identification of (20R)-protopanaxadiol from Panax ginseng as a novel anti-SARS-CoV-2 compound. (PubMed, FEBS Open Bio) - "Replication was inhibited by remdesivir, nirmatrelvir, and molnupiravir, but not by favipiravir or AT-527. A screening of 373 food-derived compounds identified (20R)-protopanaxadiol (PPD), a ginseng metabolite, as a novel inhibitor. Together, this work highlights this BAC-vectored replicon as a practical platform for antiviral screening and identifies the potential of safe, food-derived supplements in combating SARS-CoV-2."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Pharmacokinetics of injectable favipiravir: phase I, randomized, double-blind, placebo-controlled study in healthy East Asian subjects. (PubMed, Antimicrob Agents Chemother) - "No serious adverse events were observed. These findings support advancing injectable favipiravir into clinical evaluation.CLINICAL TRIALSThis study is registered with the Japan Registry of Clinical Trials as jRCT2071210042 and jRCT2071210126."

Clinical • Journal • PK/PD data • Hematological Disorders • Infectious Disease • Influenza • Respiratory Diseases • Thrombocytopenia

Betaine Alleviates Favipiravir-induced Ovarian and Uterine Toxicity by Regulating Oxidative, Inflammatory, Cellular Death, Steroidogenic, Hormonal, and Histopathological Changes. (PubMed, Reprod Sci) - "Histologically, betaine preserved tissue integrity by mitigating ovarian and uterine damage caused by FVP (p < 0.05). FVP caused multifaceted oxidative, inflammatory, apoptotic, and hormonal damage in ovarian and uterine tissues, while BTN significantly reduced these effects, preserving tissue integrity and function."

IO biomarker • Journal • Inflammation • BCL2 • BECN1 • CASP3 • CYP17A1 • CYP19A1 • IL1B • MAP1LC3A • TNFA

Chandipura Virus: An Emerging Neurological Threat Transmitted by Sandflies in India. (PubMed, Immun Inflamm Dis) - "Chandipura virus represents a re-emerging neuroinvasive arbovirus with significant public health implications in India. Strengthening AES surveillance, integrating genomic monitoring, developing rapid diagnostics, advancing antiviral and vaccine research, and implementing climate-informed vector control strategies are critical priorities. A coordinated One Health framework is essential to mitigate future outbreaks and reduce pediatric mortality."

Journal • Review • CNS Disorders • Pediatrics

Spectrum of Gastrointestinal, Hepatobiliary, and Pancreatic Involvement in Hantavirus Infection: A Narrative Review. (PubMed, Cureus) - "Antiviral therapies such as ribavirin and favipiravir have shown inconsistent or limited clinical benefits. However, the current evidence is sparse, mostly derived from case reports, case series, and small retrospective studies, which limits our understanding of GI and hepatobiliary-pancreatic manifestations in patients with hantavirus infections. Large prospective studies are needed to clarify the mechanisms, incidence, and prognostic significance of these manifestations."

Journal • Review • Autoimmune Hepatitis • Chronic Kidney Disease • Gastroenterology • Hematological Disorders • Hepatology • Immunology • Infectious Disease • Inflammation • Pain • Pancreatitis • Pulmonary Disease • Renal Disease • Respiratory Diseases

Hantavirus Infection: Review of Clinical Management. (PubMed, Acta Med Indones) - "Ribavirin may provide benefit in selected HFRS cases when given early, but evidence remains inconclusive, especially for HCPS. Favipiravir has demonstrated promising antiviral activity in vitro and in animal studies, yet clinical data in humans are still lacking...Hantavirus infection continues to represent an important global public health concern due to its potential for severe disease and high mortality. Improved understanding of disease pathogenesis, advances in diagnostic methods, and ongoing research into antiviral therapies and vaccines are essential to improve patient outcomes and strengthen future prevention strategies."

Journal • Review • Hematological Disorders • Infectious Disease • Nephrology • Renal Disease • Respiratory Diseases • Thrombocytopenia

Hantavirus: A Comprehensive Contemporary Review of Virology, Global Epidemiology, Clinical Variants, Diagnosis, Treatment, and Intensive Care Management. (PubMed, Indian J Crit Care Med) - "Ribavirin reduces mortality in HFRS when given early; no antiviral is definitively proven for HCPS...Favipiravir and monoclonal antibody therapies are under active investigation...Kumar ASA, John J. Hantavirus: A Comprehensive Contemporary Review of Virology, Global Epidemiology, Clinical Variants, Diagnosis, Treatment, and Intensive Care Management. Indian J Crit Care Med 2026;30(5):430-442."

Journal • Critical care • Hematological Disorders • Infectious Disease • Nephrology • Renal Disease • Respiratory Diseases

Critical updates in the 2024 influenza clinical practice guidelines of the World Health Organization. (PubMed, Infect Dis Immun) - "Baloxavir is not recommended for non-severe cases without severe risk factors, and other antivirals like oseltamivir, laninamivir, peramivir, zanamivir, favipiravir, and arbidol are not recommended for non-severe patients...Resource availability and co-infections can influence guideline implementation. Further research is needed to identify optimal strategies for specific populations."

Clinical guideline • Journal • Infectious Disease • Influenza • Obesity • Respiratory Diseases

Favipiravir tissue distribution and inhibitory quotients in preclinical models: towards a pipeline for evidence-based antiviral repurposing. (PubMed, J Antimicrob Chemother) - "Tissue-based IQs refine the interpretation of exposure-response relationships and help explain favipiravir's variable in vivo performance. The same framework can be refined and applied to other antiviral candidates to support preparedness strategies."

Journal • Preclinical • Chikungunya • Infectious Disease • Influenza • Novel Coronavirus Disease • Respiratory Diseases